High-density lipoprotein therapeutics and cardiovascular prevention

Journal of Clinical Lipidology

Volumn 4, Issue 5, 2010, Pages 411-419

  Fazio, Sergio ^a   Linton, MacRae F ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

apoAI; CETP; Cholesterol efflux; HDL; LXR; Reverse cholesterol transport

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A1 MILANO; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PROBUCOL SUCCINATE; UNCLASSIFIED DRUG;

ATHEROMA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; CORRELATION ANALYSIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LIFESTYLE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION;

APOLIPOPROTEIN A-I; CARDIOVASCULAR DISEASES; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CLINICAL TRIALS AS TOPIC; HUMANS; LIPOPROTEINS, HDL; PROBUCOL;

EID: 77957862279     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2010.08.004     Document Type: Review

References (95)

1. S. Hulley, P. Ashman, L. Kuller, N. Lasser, and R. Sherwin HDL-cholesterol levels in the Multiple Risk Factor Intervention Trial (MRFIT) by the MRFIT Research Group 1,2 Lipids 14 1979 119 123
2. A. Keys Alpha lipoprotein (HDL) cholesterol in the serum and the risk of coronary heart disease and death Lancet 2 1980 603 606
3. W.A. Ghali, and N. Rodondi HDL cholesterol and cardiovascular risk BMJ 338 2009 a3065
4. S. Fazio, and M.F. Linton Elevated high-density lipoprotein (HDL) levels due to hepatic lipase mutations do not reduce cardiovascular disease risk: another strike against the HDL dogma J Clin Endocrinol Metab 94 2009 1081 1083
5. S. Fazio, and M.F. Linton Sorting out the complexities of reverse cholesterol transport: CETP polymorphisms, HDL, and coronary disease J Clin Endocrinol Metab 91 2006 3273 3275
6. S. Fazio, and M.F. Linton Apolipoprotein AI as therapy for atherosclerosis: does the future of preventive cardiology include weekly injections of the HDL protein? Mol Interv 3 2003 436 440
7. G. Franceschini, C.R. Sirtori, A. Capurso 2nd, K.H. Weisgraber, and R.W. Mahley A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family J Clin Invest 66 1980 892 900
8. B. Agerholm-Larsen, B.G. Nordestgaard, R. Steffensen, G. Jensen, and A. Tybjaerg-Hansen Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene Circulation 101 2000 1907 1912
9. S.E. Borggreve, H.L. Hillege, and G.M. Dallinga-Thie High plasma cholesteryl ester transfer protein levels may favour reduced incidence of cardiovascular events in men with low triglycerides Eur Heart J 28 2007 1012 1018
10. Y. Saito Is cholesteryl ester transfer protein (CETP) deficiency atherogenic in familial hypercholesterolemia Intern Med 37 1998 495 496
11. S. Zhong, D.S. Sharp, J.S. Grove, C. Bruce, K. Yano, J.D. Curb, and A.R. Tall Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels J Clin Invest 97 1996 2917 2923
12. S.E. Borggreve, H.L. Hillege, and B.H. Wolffenbuttel An increased coronary risk is paradoxically associated with common cholesteryl ester transfer protein gene variations that relate to higher high-density lipoprotein cholesterol: a population-based study J Clin Endocrinol Metab 91 2006 3382 3388
13. T.H. Johannsen, P.R. Kamstrup, and R.V. Andersen Hepatic lipase, genetically elevated high-density lipoprotein, and risk of ischemic cardiovascular disease J Clin Endocrinol Metab 94 2009 1264 1273
14. P. Barter Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial Am J Cardiol 104 2009 10E 15E
15. P.J. Barter, M. Caulfield, and M. Eriksson Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2007 2109 2122
16. W.A. van der Steeg, I. Holme, and S.M. Boekholdt High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies J Am Coll Cardiol 51 2008 634 642
17. E.M. deGoma, R.L. deGoma, and D.J. Rader Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches J Am Coll Cardiol 51 2008 2199 2211
18. K.A. Rye, C.A. Bursill, G. Lambert, F. Tabet, and P.J. Barter The metabolism and anti-atherogenic properties of HDL J Lipid Res 50 Suppl 2009 S195 S200
19. D. Sviridov, N. Mukhamedova, A.T. Remaley, J. Chin-Dusting, and P. Nestel Antiatherogenic functionality of high density lipoprotein: how much versus how good J Atheroscler Thromb 15 2008 52 62
20. D. Ornish, L.W. Scherwitz, and J.H. Billings Intensive lifestyle changes for reversal of coronary heart disease JAMA 280 1998 2001 2007
21. P.L. Canner, K.G. Berge, and N.K. Wenger Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin J Am Coll Cardiol 8 1986 1245 1255
22. M.J. Chapman, G. Assmann, J.C. Fruchart, J. Shepherd, and C. Sirtori Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid - a position paper developed by the European Consensus Panel on HDL-C Curr Med Res Opin 20 2004 1253 1268
23. G. Assmann, A. von Eckardstein, and H. Funke High density lipoproteins, reverse transport of cholesterol, and coronary artery disease. Insights from mutations Circulation 87 1993 III28 III34
24. M.P. Petraki, P.T. Mantani, and A.D. Tselepis Recent advances on the antiatherogenic effects of HDL-derived proteins and mimetic peptides Curr Pharm Des 15 2009 3146 3166
25. B.J. Ansell, G.C. Fonarow, and A.M. Fogelman The paradox of dysfunctional high-density lipoprotein Curr Opin Lipidol 18 2007 427 434
26. S. Acton, A. Rigotti, K.T. Landschulz, S. Xu, H.H. Hobbs, and M. Krieger Identification of scavenger receptor SR-BI as a high density lipoprotein receptor Science 271 1996 518 520
27. R. McPherson, and Y. Marcel Role of cholesteryl ester transfer protein in reverse cholesterol transport Clin Cardiol 14 1991 I31 I34
28. M. Navab, G.M. Anantharamaiah, S.T. Reddy, B.J. Van Lenten, B.J. Ansell, and A.M. Fogelman Mechanisms of disease: proatherogenic HDL - an evolving field Nat Clin Pract Endocrinol Metab 2 2006 504 511
29. A. Braun, B.L. Trigatti, and M.J. Post Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice Circ Res 90 2002 270 276
30. J.H. Graversen, G. Castro, and A. Kandoussi A pivotal role of the human kidney in catabolism of HDL protein components apolipoprotein A-I and A-IV but not of A-II Lipids 43 2008 467 470
31. S.M. Hammad, J.L. Barth, C. Knaak, and W.S. Argraves Megalin acts in concert with cubilin to mediate endocytosis of high density lipoproteins J Biol Chem 275 2000 12003 12008
32. V.I. Zannis, A. Chroni, and M. Krieger Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL J Mol Med 84 2006 276 294
33. I. Lorenzi, A. von Eckardstein, S. Radosavljevic, and L. Rohrer Lipidation of apolipoprotein A-I by ATP-binding cassette transporter (ABC) A1 generates an interaction partner for ABCG1 but not for scavenger receptor BI Biochim Biophys Acta 1781 2008 306 313
34. A.M. Vaughan, and J.F. Oram ABCA1 and ABCG1 or ABCG4 act sequentially to remove cellular cholesterol and generate cholesterol-rich HDL J Lipid Res 47 2006 2433 2443
35. P.G. Yancey, W.G. Jerome, and H. Yu Severely altered cholesterol homeostasis in macrophages lacking apoE and SR-BI J Lipid Res 48 2007 1140 1149
36. T. Vaisar, S. Pennathur, and P.S. Green Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL J Clin Invest 117 2007 746 756
37. M. Navab, G.M. Ananthramaiah, and S.T. Reddy The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL J Lipid Res 45 2004 993 1007
38. F.D. Brites, J. Verona, L.E. Schreier, J.C. Fruchart, G.R. Castro, and R.L. Wikinski Paraoxonase 1 and platelet-activating factor acetylhydrolase activities in patients with low hdl-cholesterol levels with or without primary hypertriglyceridemia Arch Med Res 35 2004 235 240
39. B.J. Van Lenten, S.Y. Hama, and F.C. de Beer Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures J Clin Invest 96 1995 2758 2767
40. A. Kontush, E.C. de Faria, S. Chantepie, and M.J. Chapman Antioxidative activity of HDL particle subspecies is impaired in hyperalphalipoproteinemia: relevance of enzymatic and physicochemical properties Arterioscler Thromb Vasc Biol 24 2004 526 533
41. D. De Bacquer, G. De Backer, M. Langlois, J. Delanghe, H. Kesteloot, and M. Kornitzer Haptoglobin polymorphism as a risk factor for coronary heart disease mortality Atherosclerosis 157 2001 161 166
42. A.P. Levy Haptoglobin: a major susceptibility gene for diabetic cardiovascular disease Isr Med Assoc J 6 2004 308 310
43. A.P. Levy, H.C. Gerstein, and R. Miller-Lotan The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes Diabetes Care 27 2004 2767
44. S. Blum, U. Milman, and C. Shapira Dual therapy with statins and antioxidants is superior to statins alone in decreasing the risk of cardiovascular disease in a subgroup of middle-aged individuals with both diabetes mellitus and the haptoglobin 2-2 genotype Arterioscler Thromb Vasc Biol 28 2008 e18 e20
45. J. White, T. Guerin, and H. Swanson Diabetic HDL-associated myristic acid inhibits acetylcholine-induced nitric oxide generation by preventing the association of endothelial nitric oxide synthase with calmodulin Am J Physiol Cell Physiol 294 2008 C295 C305
46. X. Wang, H.L. Collins, and M. Ranalletta Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo J Clin Invest 117 2007 2216 2224
47. I.M. Singh, M.H. Shishehbor, and B.J. Ansell High-density lipoprotein as a therapeutic target: a systematic review JAMA 298 2007 786 798
48. B.J. Ansell, K.E. Watson, A.M. Fogelman, M. Navab, and G.C. Fonarow High-density lipoprotein function recent advances J Am Coll Cardiol 46 2005 1792 1798
49. B. Zhang, J. Menzin, M. Friedman, J.R. Korn, and R.T. Burge Predicted coronary risk for adults with coronary heart disease and low HDL-C: an analysis from the US National Health and Nutrition Examination Survey Curr Med Res Opin 24 2008 2711 2717
50. T. Gordon, W.P. Castelli, M.C. Hjortland, W.B. Kannel, and T.R. Dawber High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study Am J Med 62 1977 707 714
51. B.J. Ansell, M. Navab, and S. Hama Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment Circulation 108 2003 2751 2756
52. L.R. Brunham, J.K. Kruit, and T.D. Pape Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment Nat Med 13 2007 340 347
53. M. Koseki, A. Matsuyama, and K. Nakatani Impaired insulin secretion in four Tangier disease patients with ABCA1 mutations J Atheroscler Thromb 16 2009 292 296
54. Fryirs MA, Barter PJ, Appavoo M, et al. Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion. Arterioscler Thromb Vasc Biol;30:1642-1648.
55. C. Shtir, I.S. Nagakawa, and W.L. Duren Subsets of Finns with high HDL to total cholesterol ratio show evidence for linkage to type 2 diabetes on chromosome 6q Hum Hered 63 2007 17 25
56. S.J. Nicholls, E.M. Tuzcu, and I. Sipahi Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis JAMA 297 2007 499 508
57. M. Briel, I. Ferreira-Gonzalez, and J.J. You Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis BMJ 338 2009 b92
58. Coronary Drug Project report on clofibrate and niacin Atherosclerosis 30 1978 239 240
59. A.J. Taylor, H.J. Lee, and L.E. Sullenberger The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3 Curr Med Res Opin 22 2006 2243 2250
60. A.J. Taylor, L.E. Sullenberger, H.J. Lee, J.K. Lee, and K.A. Grace Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins Circulation 110 2004 3512 3517
61. A.J. Taylor, T.C. Villines, and E.J. Stanek Extended-release niacin or ezetimibe and carotid intima-media thickness N Engl J Med 361 2009 2113 2122
62. B.G. Brown, X.Q. Zhao, and A. Chait Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease N Engl J Med 345 2001 1583 1592
63. M.H. Frick, V. Manninen, J.K. Huttunen, O.P. Heinonen, L. Tenkanen, and M. Manttari HDL-cholesterol as a risk factor in coronary heart disease. An update of the Helsinki Heart Study Drugs 40 Suppl 1 1990 7 12
64. S.J. Robins, D. Collins, and J.T. Wittes Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial JAMA 285 2001 1585 1591
65. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study Circulation 102 2000 21 27
66. A. Keech, R.J. Simes, and P. Barter Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial Lancet 366 2005 1849 1861
67. R. Scott, R. O'Brien, and G. Fulcher Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study Diabetes Care 32 2009 493 498
68. ACCORD Study Group H.N. Ginsberg, M.B. Elam, and L.C. Lovato Effects of combination lipid therapy in type 2 diabetes mellitus NEJM 362 2010 1563 1574
69. B.E. Klein Reduction in risk of progression of diabetic retinopathy N Engl J Med 363 2010 287 288
70. G.L. Anderson, M. Limacher, and A.R. Assaf Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial JAMA 291 2004 1701 1712
71. S.E. Nissen, and K. Wolski Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 356 2007 2457 2471
72. A.M. Lincoff, K. Wolski, S.J. Nicholls, and S.E. Nissen Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials JAMA 298 2007 1180 1188
73. E.B. Rimm, P. Williams, K. Fosher, M. Criqui, and M.J. Stampfer Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors BMJ 319 1999 1523 1528
74. S.E. Nissen, J.C. Tardif, and S.J. Nicholls Effect of torcetrapib on the progression of coronary atherosclerosis N Engl J Med 356 2007 1304 1316
75. M.L. Bots, F.L. Visseren, and G.W. Evans Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial Lancet 370 2007 153 160
76. M. Vergeer, M.L. Bots, and S.I. van Leuven Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials Circulation 118 2008 2515 2522
77. P. Barter, A.M. Gotto, and J.C. LaRosa HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events N Engl J Med 357 2007 1301 1310
78. L.G. Howes, and K. Kostner The withdrawal of torcetrapib from drug development: implications for the future of drugs that alter HDL metabolism Expert Opin Investig Drugs 16 2007 1509 1516
79. D. Masson Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclerosis Curr Opin Investig Drugs 10 2009 980 987
80. E.A. Stein, E.S. Stroes, and G. Steiner Safety and tolerability of dalcetrapib Am J Cardiol 104 2009 82 91
81. D. Masson, M. Koseki, and M. Ishibashi Increased HDL cholesterol and apoA-I in humans and mice treated with a novel SR-BI inhibitor Arterioscler Thromb Vasc Biol 29 2009 2054 2060
82. S.E. Nissen, T. Tsunoda, and E.M. Tuzcu Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial JAMA 290 2003 2292 2300
83. J.C. Tardif, J. Gregoire, and P.L. L'Allier Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial JAMA 297 2007 1675 1682
84. S.I. van Leuven, R.S. Birjmohun, and R. Franssen ApoAI- phosphatidylcholine infusion neutralizes the atherothrombotic effects of C-reactive protein in humans J Thromb Haemost 7 2009 347 354
85. R.M. Epand, R.F. Epand, B.G. Sayer, G. Datta, M. Chaddha, and G.M. Anantharamaiah Two homologous apolipoprotein AI mimetic peptides. Relationship between membrane interactions and biological activity J Biol Chem 279 2004 51404 51414
86. R.M. Epand, R.F. Epand, B.G. Sayer, G. Melacini, M.N. Palgulachari, J.P. Segrest, and G.M. Anantharamaiah An apolipoprotein AI mimetic peptide: membrane interactions and the role of cholesterol Biochemistry 43 2004 5073 5083
87. J.C. Tardif, J. Gregoire, and P.L. L'Allier Effects of the antioxidant succinobucol (AGI-1067) on human atherosclerosis in a randomized clinical trial Atherosclerosis 197 2008 480 486
88. J.C. Tardif, J.J. McMurray, and E. Klug Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial Lancet 371 2008 1761 1768
89. F.M. Sacks, L.L. Rudel, and A. Conner Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo J Lipid Res 50 2009 894 907
90. R. Waksman, R. Torguson, and K.M. Kent A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome J Am Coll Cardiol 55 2010 2727 2735
91. F. Briand, M. Treguier, A. Andre, D. Grillot, M. Issandou, K. Ouguerram, and T. Sulpice Liver X receptor activation promotes macrophage-to-feces reverse cholesterol transport in a dyslipidemic hamster model J Lipid Res 51 2010 763 770
92. S. Larrede, C.M. Quinn, and W. Jessup Stimulation of cholesterol efflux by LXR agonists in cholesterol-loaded human macrophages is ABCA1-dependent but ABCG1-independent Arterioscler Thromb Vasc Biol 29 2009 1930 1936
93. S.B. Joseph, B.A. Laffitte, and P.H. Patel Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors J Biol Chem 277 2002 11019 11025
94. V. Molteni, X. Li, and J. Nabakka N-Acylthiadiazolines, a new class of liver X receptor agonists with selectivity for LXRbeta J Med Chem 50 2007 4255 4259
95. D. Bailey, R. Jahagirdar, and A. Gordon RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo J Am Coll Cardiol 55 2010 2580 2589